Biotech & Genomic Medicine▼2
CRISPR Therapeutics and Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?
CRISPR Therapeutics AG and Vertex Pharmaceuticals present contrasting investment profiles for 2026, with Vertex offering a profitable, cash-generating cystic fibrosis franchise and CRISPR representing a high-risk, pure-play gene-editing bet. CRISPR's FY 2025 revenue fell roughly 90% to nearly $3.5 million, with a net loss of approximately $581.6 million, while Vertex generated close to $12 billion in revenue and net income of approximately $4.0 billion. CRISPR carries a low debt-to-equity ratio of roughly 0.2x and a current ratio of approximately 13.3x, but negative free cash flow of nearly $345.9 million, whereas Vertex posted strong free cash flow of nearly $3.2 billion with a debt-to-equity ratio of approximately 0.4x. Vertex trades at a forward P/E of 25.3x and a price-to-sales ratio of 10x, compared to CRISPR's forward P/E of 18.6x and price-to-sales ratio of 1270x. The two companies share profits from their joint gene-editing therapy CASGEVY on a 40% to 60% split, but CRISPR faces risks including a $600 million convertible note issuance in Q1 2026 and intellectual property litigation from ToolGen, while Vertex contends with revenue concentration in cystic fibrosis and clinical setbacks such as the RewinD-LB trial failure.